Durvalumab
Monoclonal antibody
Also known as MEDI4736
Evidence outlook
Approved: Non-Small Cell Lung Cancer, Hepatocellular Carcinoma, Bladder Cancer, Biliary Tract Cancer, Small Cell Lung Cancer, Endometrial Cancer, Non-Muscle Invasive Bladder Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Ovarian Cancer · Phase 3Renal Cell Carcinoma · Phase 3Urothelial Carcinoma · Phase 3
Also approved (4)
- Gastric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
- Non-Small Cell Lung Cancer (NSCLC)Imfinzi in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Imfinzi as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements (for selection criteria, see section 5.1). Imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum...
- Maintenance treatment of locally-advanced, unresectable non-small cell lung cancer following definitive chemoradiation therapy
- Locally Advanced or Metastatic Urothelial Carcinoma IMFINZI® (durvalumab for injection) is indicated for: • the treatment of patients with locally advanced or metastatic urothelial carcinoma who: - have disease progression during or following platinum-containing chemotherapy - have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Marketing authorization with conditions was based on a promising tumour response rate and durability of response. An improvement in survival or disease-related symptoms has not been established (see 14...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PACIFIC NCT02125461 · Non-Small Cell Lung Cancer Patients were randomly assigned in a 2:1 ratio and quadruple-blinded to durvalumab or matching placebo, with 476 receiving durvalumab and 237 placebo. The prespecified primary clinical endpoints were met: progression-free survival was 16.8 versus 5.6 months (HR 0.52, p<0.0001), and overall survival also favored durvalumab (HR 0.68, p=0.00251). Registry: NCT02125461 | 3 | Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.); Overall Survival (From baseline until death due to any cause. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.) 2017-02-13 | Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8) | Reliable signal | link ↗ |
View 4 more trials
ARCTIC NCT02352948 · Non - Small Cell Lung Cancer NSCLC This was a randomized, open-label, active-controlled phase 3 trial with hard clinical co-primary endpoints (overall survival and progression-free survival) in advanced NSCLC, but the key comparisons for durvalumab were not statistically significant: in sub-study B, durvalumab plus tremelimumab missed the OS and PFS superiority tests (OS HR 0.80, p=0.109; PFS HR 0.77, p=0.056), and in sub-study A, durvalumab monotherapy was underpowered with no formal statistical comparison performed. Because the primary endpoint was not met, the evidence is moderate rather than strong. Registry: NCT02352948 | 3 | Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months); Progression-Free Survival (PFS) (Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.) 2018-02-09 | Sub-study A: median OS 11.7 vs 6.8 months, HR 0.63 (95% CI 0.42-0.93); median PFS 3.8 vs 2.2 months, HR 0.71 (95% CI 0.49-1.04). Sub-study B: median OS 11.5 vs 8.7 months, HR 0.80 (95% CI 0.61-1.05; p=0.109); median PFS 3.5 vs 3.5 months, HR 0.77 (95% CI 0.59-1.01; p=0.056). | Partial signal | link ↗ |
PACIFIC2 NCT03519971 · Non-Small Cell Lung Cancer The study was randomized, double-blind, and placebo-controlled, with 219 participants receiving durvalumab and 109 receiving placebo alongside standard chemoradiation. Its primary clinical endpoint, progression-free survival, was not statistically significantly improved with durvalumab (13.8 vs 9.4 months; hazard ratio 0.85, p=0.247), so the results provide meaningful but inconclusive evidence of benefit. Registry: NCT03519971 | 3 | Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).) 2023-09-07 | Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) | Partial signal | link ↗ |
AEGEAN NCT03800134 · Non-Small Cell Lung Cancer This was a randomized, double-blind, placebo-controlled trial, and both primary endpoints were met: event-free survival (hazard ratio 0.68, p=0.004) and pathological complete response (17.2% vs 4.3%). The sources available for this trial do not report a sample-size (power) calculation, so it cannot be confirmed that the trial was adequately powered. Registry: NCT03800134 | 3 | Pathological Complete Response (pCR) in modified intent-to-treat (mITT) population (Up to approximately 15 weeks after randomization); Event-Free Survival (EFS) in modified intent to treat (mITT) population (Up to 5.5 years after first patient randomized.) 2022-11-10 | Co-primary endpoints, perioperative durvalumab + neoadjuvant chemotherapy vs placebo + chemotherapy: event-free survival hazard ratio 0.68 (95% CI 0.53 to 0.88), p=0.004 at the first interim analysis; pathological complete response 17.2% vs 4.3%, difference 13.0 percentage points (95% CI 8.7 to 17.6), p<0.001 at interim (Heymach et al., N Engl J Med 2023). | Partial signal | link ↗ |
POSEIDON NCT03164616 · Non-Small Cell Lung Cancer This was a large randomized trial with a chemotherapy control arm, but it was open-label, so neither patients nor doctors were blinded. Progression was read by a blinded independent central review and survival is objective, so the open-label design does not bias these endpoints. Of its two primary endpoints, progression-free survival improved significantly (hazard ratio 0.74) while overall survival did not (hazard ratio 0.86, p=0.076), so the result is mixed. Registry: NCT03164616 | 3 | Progression-Free Survival (PFS); D + SoC Compared With SoC Alone (Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).); Overall Survival (OS); D + SoC Compared With SoC Alone (From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).) 2021-03-12 | Primary endpoints, durvalumab + chemotherapy vs chemotherapy alone: progression-free survival median 5.5 vs 4.8 months, hazard ratio 0.74 (95% CI 0.620 to 0.885), p=0.00093, met; overall survival median 13.3 vs 11.7 months, hazard ratio 0.86 (95% CI 0.724 to 1.016), p=0.07581, not significant (CT.gov posted results). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (71)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (417)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (101)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (145)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (20)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (26)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other PD-L1 drugs
Atezolizumab, Avelumab, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), Adebrelimab, Envafolimab and 7 more. Compare all 13 PD-L1 drugs
This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Biliary Tract Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Durvalumab: this drug | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6) | |
| Zanidatamab | Approved | Multispecific antibody | HER2 | Weak signal | NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023) | |
| Futibatinib (Lytgobi) | Phase 3 | Small molecule | FGFR (FGFR1/2/3/4) | not yet graded | No reviewed efficacy summary in this indication | |
| Ivonescimab | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tovecimig | Phase 2/3 | Multispecific antibody | DLL4 x VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Phase 2 | Monoclonal antibody | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| IBC-Ab002 | Phase 1(overall) | Monoclonal antibody | PD-L1 | Partial signal(overall) | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(204 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Durvalumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (32)
November 2026 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
December 2026 (26)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (81)
January 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2027 (4)
What to watch
What to watch
What to watch
What to watch
March 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2027 (1)
What to watch
May 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (4)
What to watch
What to watch
What to watch
What to watch
September 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
October 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
November 2027 (1)
What to watch
December 2027 (16)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (43)
January 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
February 2028 (3)
What to watch
What to watch
What to watch
March 2028 (4)
What to watch
What to watch
What to watch
What to watch
April 2028 (2)
May 2028 (2)
June 2028 (2)
July 2028 (3)
What to watch
What to watch
What to watch
August 2028 (2)
September 2028 (3)
What to watch
What to watch
What to watch
October 2028 (4)
What to watch
What to watch
What to watch
November 2028 (4)
What to watch
What to watch
What to watch
What to watch
December 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (24)
January 2029 (2)
February 2029 (3)
What to watch
What to watch
What to watch
March 2029 (1)
What to watch
April 2029 (1)
What to watch
May 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (4)
What to watch
What to watch
What to watch
What to watch
August 2029 (3)
What to watch
What to watch
What to watch
September 2029 (3)
What to watch
What to watch
What to watch
October 2029 (3)
What to watch
What to watch
What to watch
November 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (16)
January 2030 (3)
What to watch
What to watch
What to watch
February 2030 (1)
What to watch
March 2030 (1)
What to watch
April 2030 (3)
What to watch
What to watch
May 2030 (4)
What to watch
What to watch
What to watch
What to watch
June 2030 (1)
What to watch
August 2030 (1)
What to watch
December 2030 (2)
What to watch
What to watch
2031 (3)
June 2031 (1)
What to watch
November 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (3)
May 2032 (1)
What to watch
July 2032 (1)
What to watch
August 2032 (1)
What to watch
2033 (1)
January 2033 (1)
What to watch
2039 (1)
July 2039 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent